Glucagen Hypokit

Glucagen Hypokit is a glucagon‑containing solution for injection used in the European market. The product delivers the hormone glucagon in a sterile liquid form that can be administered intramuscularly, intravenously, or subcutaneously. It is prescribed for rapid reversal of severe hypoglycemia when oral glucose is not feasible. Glucagen Hypokit is a prescription‑only medication and is not classified as a controlled substance. The kit includes a ready‑to‑use syringe for emergency administration.

Glucagen Hypokit is indicated for the treatment of severe hypoglycemia in patients with diabetes when rapid glucose elevation is required.

- Immediate correction of blood glucose in unconscious or unable‑to‑eat patients. - Use when oral carbohydrate therapy is ineffective or impractical. - Administration by trained caregivers, healthcare professionals, or patients themselves in emergency settings. - Suitable for both type 1 and type 2 diabetes patients experiencing insulin‑induced hypoglycemia. - Can be employed in hospital, ambulatory, or home environments as part of a hypoglycemia management plan.

The safety profile of Glucagen Hypokit reflects the pharmacologic actions of glucagon and the injection process.

Common: - Nausea or vomiting, typically occurring within minutes after administration. - Transient headache, dizziness, or feeling of warmth. - Mild pain, redness, or swelling at the injection site. - Flushing or a sensation of heat spreading through the body.

Serious: - Signs of an allergic reaction, including hives, swelling of the face or throat, or difficulty breathing. - Cardiovascular events such as rapid heart rate, irregular heartbeat, or chest discomfort. - Severe hypoglycemia rebound (hyperglycemia) if dosing is excessive.

These effects are generally short‑lived, but monitoring after administration is recommended.

When using Glucagen Hypokit, certain precautions should be observed to ensure safe and effective treatment of hypoglycemia.

- Verify the patient’s diagnosis of hypoglycemia before administration. - Ensure correct reconstitution and dosage according to the product instructions. - Avoid use in patients with known hypersensitivity to glucagon or any excipients. - Monitor blood glucose levels after injection to confirm response and prevent hyperglycemia. - Use caution in patients with pheochromocytoma, adrenal insufficiency, or cardiac disease. - Store the kit at controlled room temperature and protect from light. - Dispose of used syringes in accordance with local hazardous‑waste regulations.

Glucagen Hypokit may interact with other medications or substances that affect glucose metabolism or cardiovascular function.

Avoid: - Beta‑blockers, which can mask typical glucagon‑induced symptoms such as tachycardia. - Insulin or oral hypoglycemic agents taken immediately before glucagon, which may increase risk of rapid glucose fluctuations. - Monoamine oxidase inhibitors (MAOIs) that could potentiate cardiovascular effects.

Use with caution: - Catecholamine‑releasing drugs (e.g., epinephrine) that may augment heart rate and blood pressure changes. - Digoxin or other cardiac glycosides, requiring monitoring of cardiac rhythm. - Anticholinergic agents, which might affect gastrointestinal motility and glucagon absorption.